Ashish Tripathi, founder and CEO of Tzar Labs, as well as chairman of Epigeneres Biotech, the Indian firm where the test was first developed in 2021, has published a study this month in the journal Stem Cells, saying that they have found a breakthrough 'holy grail' of cancer detection that predicts tumors a year before they form.
Following a radically successful trial on cancer patients, a new blood test that promises to predict tumors more than a year before they begin to form is now being applied in hospitals across the United Kingdom.
“This is the first pan-cancer blood test,” said Ashish Tripathi, founder and CEO of Tzar Labs as well as chairman of Epigeneres Biotech, the Indian firm where the test was first developed in 2021. An updated report on their findings was published this month in the journal Stem Cells.
“We can detect [cancer] earlier than other known technologies … before the tumor has physically formed,” Tripathi continued during a new...